Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.

Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M, Taylor RS.

Int J Technol Assess Health Care. 2014 Jul;30(3):312-24. doi: 10.1017/S0266462314000300.

PMID:
25308694
2.

Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?

Uttley L, Tappenden P.

Curr Opin Pulm Med. 2014 Nov;20(6):607-12. doi: 10.1097/MCP.0000000000000109.

PMID:
25221853
3.

Identification and review of cost-effectiveness model parameters: a qualitative study.

Kaltenthaler E, Essat M, Tappenden P, Paisley S.

Int J Technol Assess Health Care. 2014 Jul;30(3):333-40. doi: 10.1017/S0266462314000245. Epub 2014 Aug 4.

PMID:
25089856
4.

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC, Luqmani R.

Pharmacoeconomics. 2014 Dec;32(12):1171-83. doi: 10.1007/s40273-014-0189-z.

5.

Avoiding and identifying errors and other threats to the credibility of health economic models.

Tappenden P, Chilcott JB.

Pharmacoeconomics. 2014 Oct;32(10):967-79. doi: 10.1007/s40273-014-0186-2.

PMID:
25027943
6.

Distributional Cost-Effectiveness Analysis of Health Care Programmes - A Methodological Case Study of the UK Bowel Cancer Screening Programme.

Asaria M, Griffin S, Cookson R, Whyte S, Tappenden P.

Health Econ. 2015 Jun;24(6):742-54. doi: 10.1002/hec.3058. Epub 2014 May 2.

PMID:
24798212
7.

The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.

Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C, Brownlee K.

Pharmacoeconomics. 2014 Feb;32(2):159-72. doi: 10.1007/s40273-013-0122-x.

PMID:
24338264
8.

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.

Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, Crossan C, Westby M, Anagnostou A, Taylor S, Mavranezouli I, Wonderling D, Alderson P, Ruiz F.

Health Technol Assess. 2013 Dec;17(58):v-vi, 1-192. doi: 10.3310/hta17580.

9.

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.

Uttley L, Harnan S, Cantrell A, Taylor C, Walshaw M, Brownlee K, Tappenden P.

Eur Respir Rev. 2013 Dec;22(130):476-86. doi: 10.1183/09059180.00001513. Review.

10.

Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.

Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C, Cantrell A.

Health Technol Assess. 2013 Dec;17(56):v-xvii, 1-181. doi: 10.3310/hta17560. Review.

11.

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS).

Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A.

BMJ Open. 2013 Nov 4;3(11):e003573. doi: 10.1136/bmjopen-2013-003573.

12.

Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments.

Kaltenthaler E, Tappenden P, Paisley S.

Value Health. 2013 Jul-Aug;16(5):830-6. doi: 10.1016/j.jval.2013.04.009. Epub 2013 Jun 19.

PMID:
23947977
13.

Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model.

Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R, Tappenden J.

Value Health. 2013 Jun;16(4):542-53. doi: 10.1016/j.jval.2013.02.012. Epub 2013 May 16.

PMID:
23796288
15.

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.

Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JP, Bakhai A.

Pharmacoeconomics. 2013 Apr;31(4):269-75. doi: 10.1007/s40273-013-0036-7. Review.

PMID:
23512147
16.

Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.

Sharp L, Tilson L, Whyte S, Ceilleachair AO, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M, Comber H.

BMC Health Serv Res. 2013 Mar 19;13:105. doi: 10.1186/1472-6963-13-105.

17.

Reply: cost-effectiveness of population-based screening for colorectal cancer.

Sharp L, Walsh C, Whyte S, Tilson L, O'Ceilleachair A, Usher C, Tappenden P, Chilcott J, Staines A, Barry M, Comber H.

Br J Cancer. 2013 Mar 19;108(5):1211-2. doi: 10.1038/bjc.2012.491. Epub 2013 Feb 7. No abstract available.

18.

Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.

Tappenden P, Chilcott J, Brennan A, Squires H, Stevenson M.

Value Health. 2012 Dec;15(8):1127-36. doi: 10.1016/j.jval.2012.07.008. Epub 2012 Oct 25.

PMID:
23244816
19.

The clinical effectiveness and cost-effectiveness of home-based, nurse-led health promotion for older people: a systematic review.

Tappenden P, Campbell F, Rawdin A, Wong R, Kalita N.

Health Technol Assess. 2012;16(20):1-72. doi: 10.3310/hta16200. Review.

20.

Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.

Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M, Comber H.

Br J Cancer. 2012 Feb 28;106(5):805-16. doi: 10.1038/bjc.2011.580. Epub 2012 Feb 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk